• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

囊性纤维化跨膜电导调节因子调节剂可减弱健康供体和 COVID-19 患者血液中的血小板活化和聚集。

Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.

机构信息

Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.

Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.

出版信息

Eur Respir J. 2023 Mar 23;61(3). doi: 10.1183/13993003.02009-2022. Print 2023 Mar.

DOI:10.1183/13993003.02009-2022
PMID:36958745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10033930/
Abstract

https://bit.ly/3HJykdt

摘要

点击此处

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6e3/10033930/c219c2d91f91/ERJ-02009-2022.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6e3/10033930/c219c2d91f91/ERJ-02009-2022.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6e3/10033930/c219c2d91f91/ERJ-02009-2022.01.jpg

相似文献

1
Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.囊性纤维化跨膜电导调节因子调节剂可减弱健康供体和 COVID-19 患者血液中的血小板活化和聚集。
Eur Respir J. 2023 Mar 23;61(3). doi: 10.1183/13993003.02009-2022. Print 2023 Mar.
2
Cystic fibrosis heterozygotes do not have increased platelet activation.囊性纤维化杂合子不会出现血小板活化增加的情况。
Thromb Res. 2007;121(2):159-62. doi: 10.1016/j.thromres.2007.04.004. Epub 2007 May 29.
3
Cystic fibrosis transmembrane conductance-regulator modulators for children.用于儿童的囊性纤维化跨膜传导调节因子调节剂
Lancet Respir Med. 2017 Jul;5(7):536-537. doi: 10.1016/S2213-2600(17)30208-4. Epub 2017 Jun 9.
4
Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.优化囊性纤维化患者的护理和生活质量：囊性纤维化跨膜电导调节剂的影响。
Br J Hosp Med (Lond). 2021 Nov 2;82(11):1-6. doi: 10.12968/hmed.2021.0530. Epub 2021 Nov 22.
5
How do cystic fibrosis transmembrane conductance regulator mutations produce lung disease?囊性纤维化跨膜传导调节因子突变如何导致肺部疾病？
Curr Opin Pulm Med. 1995 Nov;1(6):435-43. doi: 10.1097/00063198-199511000-00002.
6
A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.囊性纤维化跨膜电导调节因子基因调节剂在儿科患者中的应用综述。
J Pediatr Health Care. 2019 May-Jun;33(3):356-364. doi: 10.1016/j.pedhc.2018.08.013.
7
The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.囊性纤维化跨膜电导调节因子调节剂在囊性纤维化中的肺外作用。
Ann Am Thorac Soc. 2020 Feb;17(2):147-154. doi: 10.1513/AnnalsATS.201909-671CME.
8
R248G cystic fibrosis transmembrane conductance regulator mutation in three siblings presenting with recurrent acute pancreatitis and reproductive issues: a case series.三名患有复发性急性胰腺炎和生殖问题的兄弟姐妹中的R248G囊性纤维化跨膜传导调节因子突变：病例系列
J Med Case Rep. 2017 Feb 15;11(1):42. doi: 10.1186/s13256-016-1181-3.
9
A growing trend: CFTR modulators for cystic fibrosis lung transplant recipients.一种日益增长的趋势：用于囊性纤维化肺移植受者的CFTR调节剂
J Heart Lung Transplant. 2022 Feb;41(2):127-128. doi: 10.1016/j.healun.2021.10.003. Epub 2021 Oct 23.
10
Novel, mechanism-based therapies for cystic fibrosis.针对囊性纤维化的新型、基于机制的疗法。
Curr Opin Pediatr. 2005 Jun;17(3):385-92. doi: 10.1097/01.mop.0000158846.95469.6f.

本文引用的文献

1
Loss of endothelial CFTR drives barrier failure and edema formation in lung infection and can be targeted by CFTR potentiation.内皮细胞囊性纤维化跨膜传导调节因子（CFTR）的缺失会导致肺部感染时屏障功能衰竭和水肿形成，CFTR增强剂可作为治疗靶点。
Sci Transl Med. 2022 Dec 7;14(674):eabg8577. doi: 10.1126/scitranslmed.abg8577.
2
Aspirin use Reduces Platelet Hyperreactivity and Degranulation in COVID-19 Patients.阿司匹林的使用可降低COVID-19患者的血小板高反应性和脱颗粒作用。
Semin Thromb Hemost. 2023 Feb;49(1):92-96. doi: 10.1055/s-0042-1744281. Epub 2022 Mar 7.
3
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
非危重症 COVID-19 住院患者中 P2Y12 抑制剂对无器官支持生存的影响：一项随机临床试验。
JAMA. 2022 Jan 18;327(3):227-236. doi: 10.1001/jama.2021.23605.
4
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 患者住院期间使用阿司匹林（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Jan 8;399(10320):143-151. doi: 10.1016/S0140-6736(21)01825-0. Epub 2021 Nov 17.
5
Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension.CFTR 在肺动脉高压发病机制中的作用。
Eur Respir J. 2021 Nov 25;58(5). doi: 10.1183/13993003.00653-2020. Print 2021 Nov.
6
Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype.CFTR 功能障碍的内皮细胞的转录组分析揭示了一种促炎表型。
Eur Respir J. 2021 Apr 22;57(4). doi: 10.1183/13993003.00261-2020. Print 2021 Apr.
7
Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy.新型冠状病毒肺炎肺炎中的免疫血栓调节紊乱与呼吸衰竭和凝血病有关。
Circulation. 2020 Sep 22;142(12):1176-1189. doi: 10.1161/CIRCULATIONAHA.120.048488. Epub 2020 Jul 28.
8
Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19).研究 2019 年冠状病毒病的病理生理学：柏林前瞻性 COVID-19 患者队列研究方案（Pa-COVID-19）。
Infection. 2020 Aug;48(4):619-626. doi: 10.1007/s15010-020-01464-x. Epub 2020 Jun 13.
9
Neutrophil extracellular traps in COVID-19.中性粒细胞胞外陷阱在 COVID-19 中的作用。
JCI Insight. 2020 Jun 4;5(11):138999. doi: 10.1172/jci.insight.138999.
10
Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation.血小板中囊性纤维化跨膜电导调节因子功能障碍导致肺部过度炎症。
J Clin Invest. 2020 Apr 1;130(4):2041-2053. doi: 10.1172/JCI129635.